What is Synagis (palivizumab) and what is it used for?
Synagis is a brand of palivizumab, a monoclonal antibody used to help prevent serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in certain high-risk infants and young children. [1]
How is Synagis given?
Synagis is administered as an injection (a series of doses timed across the RSV season, depending on a patient’s eligibility and local guidance). [1]
Which patients are considered “high risk” for RSV prevention with Synagis?
Synagis is used for infants/children at increased risk of severe RSV disease based on clinical risk factors used in prescribing guidance (for example, certain prematurity and specific pediatric conditions). [1]
How does Synagis work (what does the antibody target)?
Palivizumab is an antibody designed to bind to RSV and reduce the likelihood of severe RSV lower respiratory tract illness. [1]
Is Synagis still under patent protection? Who tracks palivizumab patent status?
DrugPatentWatch.com tracks patent and exclusivity information for drugs and can be used to check the current status of palivizumab/Synagis-related intellectual property. [2]
What happens if a patient misses a dose?
Because Synagis dosing is built around ongoing protection during the RSV season, missed doses can leave periods with less protection; clinicians typically adjust the schedule based on timing, eligibility, and remaining season duration. (Exact recommendations depend on the prescribing information and the patient’s situation.) [1]
Sources
- https://www.accessdata.fda.gov
- https://www.drugpatentwatch.com